Sessions are scheduled in local time (CEST)
Browsing Over 485 Presentations
Sort By
Optimal treatment strategies in early breast cancer
Triple-negative breast cancer (TNBC): It’s not one size fits all (ID 203)
Lecture Time
14:20 - 14:40
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Peter Schmid (London, United Kingdom)
Authors
- Peter Schmid (London, United Kingdom)
Targeted options for advanced luminal breast cancers
From SERMs to SERDs: Advances and challenges in the development of novel agents (focus on biomarkers) (ID 198)
Lecture Time
14:20 - 14:40
Session Name
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Otto Metzger (Boston, MA, United States of America)
Authors
- Otto Metzger (Boston, MA, United States of America)
Proffered Paper session 1
Q&A and discussion (ID 214)
Lecture Time
15:18 - 15:28
Session Name
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:28
Speakers
- To be Announced (Barcelona, Spain)
Authors
- To be Announced (Barcelona, Spain)
Selecting biomarkers to inform neoadjuvant strategies
Biomarkers beyond PD-L1 to inform neoadjuvant immunotherapies in TNBC (ID 193)
Lecture Time
14:20 - 14:40
Room
Munich Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Carsten Denkert (Marburg, Germany)
Authors
- Carsten Denkert (Marburg, Germany)
Proffered Paper session 1
Invited Discussant 185O and 186O (ID 209)
Lecture Time
14:24 - 14:34
Session Name
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:28
Speakers
- Gustavo Werutsky (Porto Alegre, Brazil)
Authors
- Gustavo Werutsky (Porto Alegre, Brazil)
Optimal treatment strategies in early breast cancer
Breast conservation and axillary management after neo-adjuvant therapy (ID 204)
Lecture Time
14:40 - 15:00
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Oreste D. Gentilini (Milan, Italy)
Authors
- Oreste D. Gentilini (Milan, Italy)
Targeted options for advanced luminal breast cancers
Luminal HER2 positive vs luminal HER2 negative: Different drivers of endocrine resistance and the role of CDK4/6 inhibitors (ID 199)
Lecture Time
14:40 - 15:00
Session Name
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Luca Malorni (Prato, Italy)
Authors
- Luca Malorni (Prato, Italy)
Selecting biomarkers to inform neoadjuvant strategies
At the crossroad of de-escalation vs escalation in HER2 positive breast cancer: Which biomarkers can help in the neoadjuvant setting? (ID 194)
Lecture Time
14:40 - 15:00
Room
Munich Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Jee Hyun Kim (Seongnam, Korea, Republic of)
Authors
- Jee Hyun Kim (Seongnam, Korea, Republic of)
Proffered Paper session 1
Q&A and discussion (ID 210)
Lecture Time
14:34 - 14:44
Session Name
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:28
Speakers
- To be Announced (Barcelona, Spain)
Authors
- To be Announced (Barcelona, Spain)
Optimal treatment strategies in early breast cancer
Adjuvant radiation: Standards of care in 2023 (ID 205)
Lecture Time
15:00 - 15:20
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Orit Kaidar-Person (Ramat Gan, Israel)
Authors
- Orit Kaidar-Person (Ramat Gan, Israel)
Targeted options for advanced luminal breast cancers
Digital interactions in the management of targeted treatment (ID 200)
Lecture Time
15:00 - 15:20
Session Name
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Ines V. Vaz Luis (Villejuif, France)
Authors
- Ines V. Vaz Luis (Villejuif, France)
Selecting biomarkers to inform neoadjuvant strategies
Points to consider in the development of biomarkers in the neoadjuvant setting: Regulatory perspectives (ID 195)
Lecture Time
15:00 - 15:20
Room
Munich Hall
Date
Thu, 11.05.2023
Time
14:00 - 15:30
Speakers
- Jonas Bergh (Solna, Sweden)
Authors
- Jonas Bergh (Solna, Sweden)